Logo for Digestive Disease Week 2022

DDW Product Theater

Product Theaters are turnkey, 45-minute marketing presentations about a company’s products or services. These sessions do not offer CME credit; rather, they give industry supporters the freedom to create a presentation centered on their company’s products.

Logo for Digestive Disease Week 2022

DDW Product Theater

Product Theaters are turnkey, 45-minute marketing presentations about your company’s products or services. These sessions do not offer CME credit; rather, they give industry supporters the freedom to create a presentation centered on their company’s products.

How can we expand our knowledge of digestive diseases and improve the lives of people living with them? Watch this video to find out and learn more about this year’s meeting.

Recorded Live from the DDW Product Theaters

View on-demand the full Product Theaters presentations from DDW 2022.

STERIS EndoscopyLiquid Nitrogen Cryotherapy in the Endoscopic Management of Barrett’s Esophagus & Esophageal Neoplasia: Updates, Current Controversies and Challenges
Janssen Biotech, Inc.

Optimizing Biologic-Naïve Patient* Outcomes in Crohn’s Disease with STELARA® (ustekinumab)
*In adults with moderately to severely active Crohn’s disease

Bristol Myers SquibbAnother Day is Dawning in the Control of UC: ZEPOSIA (Ozanimod), A Once-Daily Oral Therapy
Bristol Myers SquibbPatient Identification and Treatment of Adult Patients with Moderately to Severely Active UC with ZEPOSIA
ArdelyxAn Innovative Approach to the Treatment of Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
Janssen Biotech, Inc.

STELARA®: Data-Driven Outcomes in Ulcerative Colitis (UC) Biologic-naïve Patients*
*For adults with moderately to severely active ulcerative colitis

Castle BiosciencesThe Role of TissueCypher in the Management of Barrett’s Esophagus.
Fractyl HealthThe Duodenum: A New Therapeutic Horizon for Metabolic Disease
Eli LillyPatient Identification and Treatment of Adult Patients with Moderately to Severely Active UC with ZEPOSIA
GlaxoSmithKlineExploring Cholestatic Pruritus in PBC — Are We Even Scratching the Surface?
Madrigal PharmaceuticalsEmerging Concepts in Nonalcoholic Steatohepatitis (NASH)

STERIS Endoscopy

Liquid Nitrogen Cryotherapy in the Endoscopic Management of Barrett’s Esophagus & Esophageal Neoplasia: Updates, Current Controversies and Challenges

Janssen Biotech, Inc.

Optimizing Biologic-Naïve Patient* Outcomes in Crohn’s Disease with STELARA® (ustekinumab)

*In adults with moderately to severely active Crohn’s disease

Bristol Myers Squibb

Another Day is Dawning in the Control of UC: ZEPOSIA (Ozanimod), A Once-Daily Oral Therapy

Bristol Myers Squibb

Patient Identification and Treatment of Adult Patients with Moderately to Severely Active UC with ZEPOSIA

Ardelyx

An Innovative Approach to the Treatment of Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

Janssen Biotech, Inc.

STELARA®: Data-Driven Outcomes in Ulcerative Colitis (UC) Biologic-naïve Patients*

*For adults with moderately to severely active ulcerative colitis

Castle Biosciences

The Role of TissueCypher in the Management of Barrett’s Esophagus.

Fractyl Health

The Duodenum: A New Therapeutic Horizon for Metabolic Disease

Eli Lilly

Patient Identification and Treatment of Adult Patients with Moderately to Severely Active UC with ZEPOSIA

Live Streaming Agenda

Copyright © 2022 Digestive Disease Week®

DDW Administration. 4030 Del Ray Ave. Bethesda, MD 20814